The Addiction Psychologist Dr. Cassandra Gipson - Xylazine
Mar 11, 2024
Dr. Cassandra Gipson-Reichardt, an associate professor at the University of Kentucky, studies the alarming rise of xylazine in the illicit opioid market. She uncovers the shocking 1000% increase in xylazine-related overdoses and explains its dangerous interplay with fentanyl. Delving into community engagement, she emphasizes the importance of public health education and personalized treatment strategies. Dr. Gipson also discusses innovative research methods, advocating for better understanding and collaboration to combat the evolving addiction landscape.
AI Snips
Chapters
Transcript
Episode notes
Xylazine's Role in Drug Supply
- Xylazine is a veterinary anesthetic not approved for human use that has become an adulterant in the fentanyl drug supply.
- It alters fentanyl's effects, potentially increasing sedation and toxicity, complicating treatment.
Xylazine's Complex Pharmacology
- Xylazine belongs to adrenergic 2A receptor agonists, similar to clonidine and lofexidine used for opioid withdrawal.
- However, illicit xylazine use exacerbates withdrawal and causes unique medical complications unlike these approved drugs.
Xylazine Is Not Desired by Users
- Despite some reports, most fentanyl users do not seek out xylazine in the drug supply.
- Xylazine generally suppresses fentanyl intake and is not a preferred adulterant among users.